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Running title: Platelet 5-HT and MAO B in hypothyroidism 
 
 
• Established facts:   Female hypothyroid patients had significantly lower platelet 
serotonin concentrations, similar platelet monoamine oxidase type B activity, 
significantly higher TSH levels, and significantly lower T4 levels than euthyroid 
healthy women. 
• Novel insights: The new findings of the present study were decreased platelet 
serotonin concentrations, and the lack of any significant correlations between platelet 
biochemical markers and thyroid hormones. These results suggest that hypothyroid 
patients have an altered interaction between serotonergic system and hypothalamic-
pituitary-thyroid axis activity. 
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Abstract 
 
Background/Aim: The relationship between hypothalamic-pituitary-thyroid (HPT) axis and 
serotonergic (5-HT) system is not clear. The aim of the study was to determine platelet 
biochemical markers (5-HT concentration and monoamine oxidase /MAO-B/ activity) in 
hypothyroid patients. 
Methods: The study included 25 female medication-free hypothyroid patients in 
postoperative follow-up after total thyroidectomy due to papillary thyroid carcinoma, who 
were not treated with synthetic thyroxine (T4) for 4 weeks, and 44 age matched euthyroid 
healthy women. Platelet 5-HT concentration, platelet MAO-B activity, total T4 and thyroid 
stimulating hormone (TSH) levels were determined using spectrofluorimetric methods, 
radioimmunoassay and fluoroimmunoassay, respectively.   
Results: Hypothyroid patients had significantly higher TSH, significantly lower T4 levels and 
platelet 5-HT concentration, and unchanged platelet MAO-B acrivity than healthy subjects. A 
positive correlation between 5-HT concentration and platelet MAO-B activity, and between 
platelet MAO-B activity  and T4 in control subjects was found.  
Conclusions: Reduced platelet 5-HT concentrations in hypothyroid patients suggests a 
complex interaction between 5-HT system and HPT axis activity, which could be related to 
frequent occurrence of depressive symptoms in hypothyroid patients. The determination of 
platelet 5-HT concentration should be considered as a diagnostic tool for the evaluation of  
depressive symptoms in hypothyroid patients during hormone withdrawal procedure. 
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 Introduction 
 
          Hormones of the hypothalamic-pituitary-thyroid (HPT) axis: triiodothyronine (T3), 
thyroxine (T4), and thyroid stimulating hormone (TSH), play an important role in the 
development of the central nervous system [1], regulate the metabolism and function of 
various neurotransmitters [2-4], their receptors, second-messengers [5], and gene expression  
[6]. Evidence for the interaction between serotonin (5-hydroxytryptamine, 5-HT) and thyroid 
hormones originates mostly from the experimentally-induced hypothyroid state in animals [3]. 
Decreased 5-HT [7,8] and increased 5-hydroxyinoleacetic acid [9] concentrations were 
observed in neonatal and adult hypothyroid rats, suggesting an increased 5-HT turnover  
[7,10], while T3 administration to hypothyroid animals normalized 5-HT turnover to normal 
values [10]. 
           The relationship between HPT axis and 5-HT system in humans are scarce and focused 
on alterations of thyroid hormones in psychiatric patients.  Hypothyroidism appears in 8% of 
adult population [11], and could be one of the risk factors for the development of depression 
[12]. The augmentation therapy with T3 or T4 to different antidepressants induced remission 
in treatment resistant depressed patients [13]. In hypothyroid female patients, the treatment 
with T4 induced a significant decrease in pretreatment values of 5-HT and catecholamine 
precursor in cerebrospinal fluid [14]. A significant decrease in D-fenfluramine-induced 
cortisol response was also found in hypothyroid patients [15], probably due to a decrease in 5-
HT2A receptor sensitivity [16].  It has been hypothesized that alterations in HPT axis in non-
treated depressions, could be explained by both 5-HT and noradrenalin (NE) brain alterations 
[17]. In particular NE participates in the release of TRH (thyrotrophin releasing hormone) and 
TSH [18]. In hypothyroidism deficiency of T3 accompanied by increase in TSH in the brain 
alters the noradrenergic neurotransmission by reducing beta-adrenergic receptors [19]. 
Additional studies on TSH are scarce and inconsistent in depressed patients. Excessive 
response of TSH to the TRH challenge test has been found in 10% [20] and decreased 
response in 25% of the patients [21]. 
            Blood platelets are considered to be a limited peripheral model for the central 5-HT 
neurons due to similarities in the structure and function of 5-HT receptors and 5-HT 
transporter, expressed both in platelets and 5-HT neurons [22], while platelet biochemical 
markers (5-HT concentration, monoamine oxidase type B (MAO-B) activity) might be used 
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as peripheral biological and/or trait markers for particular symptoms in depression [23,24] or 
schizophrenia [25,26]. Platelet 5-HT originates from the peripheral pool of 5-HT which is 
synthesized in the enterochromaffin cells of the gastrointestinal tract, released via blood 
stream into platelets and stored in dense granules. Platelet 5-HT is involved in the thrombus 
formation and atherogenesis, vasoconstriction on the site of endothelial injury, has a growth 
factor role for mitogenesis of arterial smooth muscle cells, proliferation of endothelial cells, 
and in vascular inflammation, it is associated with atherogenesis by increasing the synthesis 
of interleukin-6 in vascular smooth muscle cell [27]. Besides these functions, platelet 5-HT 
acts as a neurotransmitter for the peripheral nervous system, influences gastric and intestinal 
ion secretion and intestinal motility [28], and plays an additional role as an enhancer of 
platelet aggregation [29]. The mitochondrial enzyme MAO exists in two isoforms: MAO-A 
and MAO-B, that differ in tissue distribution and substrate specificity. Platelets include only 
MAO-B isoform, which regulates the levels of exogenous, dietary amines in peripheral tissues 
(phenylethylamine), but it can also oxidize dopamine, noradrenaline, adrenaline, tryptamine 
and tyramine, and is inhibited by deprenyl [30]. When MAO-A enzyme is absent or inhibited, 
MAO-B metabolizes also 5-HT [31]. In hypothyroidism, some studies [32,33] found no 
significant differences in platelet activities between the hypothyroid patients and healthy 
subjects, while in a more recent study, difference in the mean platelet volume, with no 
changes in platelet counts, was found in patients compared to healthy controls [34]. 
         In accordance with the relationship between HPT axis and 5-HT system, we 
hypothesized that platelet biochemical markers would be altered in hypothyroid patients. The 
aim of this study was to determine platelet 5-HT concentration and platelet MAO-B activity 
in medication-free female patients in hypothyroid state induced by withdrawal of 
levothyroxine after total thyroidectomy due to papillary carcinoma and in age and sex 
matched euthyroid healthy control subjects.  
 
Patients and Methods 
 
         The study included 25 female patients (mean age 49.3 ±1.2 years; range 24-74 years) 
who had undergone total thyroidectomy due to papillary carcinoma. The average time since 
thyroidectomy was 3.4 ± 1.8 years. All patients were currently in hypothyroid state with 
elevated TSH after withdrawal of replacement T4 (levothyroxine) therapy during 4 weeks, but 
in good health and without post-operative complications such as hypoparathyroidism or 
cancer recurrence. Hypothyroid state was required to increase sensitivity of serum 
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thyroglobulin test (>2 µg/L) and radioiodine whole-body scanning (which showed no 
pathological activity) in the evaluation the effectiveness of surgical treatment [35]. Control 
group consisted of 44 female euthyroid healthy subjects (mean age 46.2 ± 8.9 years; range 28-
77 years). Control subjects with abnormal liver or thyroid function tests were excluded. Apart 
of radiological and nuclear medicine testing, control subjects were examined in the same 
manner as patients. Twelve patients and 17 healthy controls were in menopause. All subjects 
were nonsmokers and free of concomitant psychiatric and additional endocrine illnesses. 
Subjects taking antihypertensive, antiallergic, anxiolytic, antirheumatic, cholesterol lowering, 
hormonal supplemental or contraceptive therapy and  drugs affecting platelet 5-HT values 
(antidepressants) or MAO-B activity (MAO inhibitors) were excluded from the study. The 
study was approved by Local Ethics Committee and all participants gave their written 
informed consent. 
         Each patient underwent a complete medical evaluation before radiological examination 
and blood sampling. After an overnight fasting and between 8 and 10 am, 5 ml of blood was 
drawn from cubital vein into tube for the analysis of serum T4 and TSH levels. Additional 5 
ml of blood was taken in tube containing 1 ml of acid citrate dextrose anticoagulant for the 
determination of platelet 5-HT concentration and platelet MAO-B activity. Platelet-rich 
plasma (PRP) was obtained by centrifugation (935×g) for 70 s at room temperature. Platelets 
were sedimented by further centrifugation of PRP at 10 000×g for 5 min. The platelet pellet 
was washed with saline and centrifuged again. Platelet 5-HT concentrations and platelet 
MAO-B activity were determined by the spectrofluorimetric methods, as previously described 
[36] using Varian Carry Eclypse spectrofluorimeter. Platelet protein was determined by the 
method of Lowry et al. (1951). [37]   
         Serum T4 and TSH were determined by a radioimmunoassay (RIA) and time-resolved 
fluoroimmunoassay (Delfia) with the kits from Perkin-Elmer. Intra and inter assay variation 
coefficients were 3.6% for T4 and 3.5% for TSH. The range of normal values was 70-165 
nmol/l for T4 and 0.4-4.2 mU/l for TSH.  
         The results are expressed as mean ± standard deviations (S.D.). The differences between 
groups were evaluated by Mann Whitney t-test. The correlation between parameters was 
determined using Spearman’s coefficient of correlation. The criterion for significance in all test 
was P<0.05. The statistical package used was SigmaStat 3.1. 
 
Results 
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         As expected, TSH values were significantly (P<0.001) higher, and T4 significantly 
(P<0.001) lower in hypothyroid patients compared to hormone values in healthy subjects 
(Table 1). Platelet MAO-B activity did not differ significantly (P=0.120) between patients and 
control subjects (Table 1). 
          Platelet 5-HT concentration differed significantly (P<0.001) between patients and 
healthy controls (Figure 1), and 5-HT values were significantly, i.e. 35% lower in hypothyroid 
patients than in euthyroid control subjects.  
          A significant positive correlation between 5-HT levels and platelet MAO-B activity was 
found in control subjects (r=0.581; P=0.000), but not in hypothyroid patients (r=0.372; 
P=0.067). No significant correlation was observed between platelet 5-HT and T4 levels in 
healthy subjects (r=0.249; P=0.103) or in patients (r=0.115; P=0.579), or between platelet 5-
HT and TSH levels in healthy subjects (r=-0,276; P=0.070) or in patients (r=0.244; P=0.237). 
There was a significant positive correlation between platelet MAO activity and T4 levels in 
healthy controls (r=0.322; P=0.033), but not in patients (r=-0.067; P=0.75). No significant 
correlation was observed between platelet MAO activity and TSH levels in healthy subjects 
(r=0.004; P=0.98) or in patients (r=0.131; P=0.529).  
 
 
         Discussion 
 
         The main finding of the present study was that subjects in pronounced hypothyroid state, 
induced by withdrawal of replacement T4 therapy after thyroidectomy, had significantly 
lower platelet 5-HT concentrations than euthyroid control subjects. This is the first study 
showing reduced platelet 5-HT concentration in hypothyroid patients, and these data suggest 
that hypothyroidism influences peripheral i.e. platelet 5-HT system. 
         A reduced platelet 5-HT concentration is associated to female gender, comorbid 
diagnosis, alcoholism, suicidal behaviour, or antidepressant treatment. The effect of sex [23, 
24,25,26,38]  was excluded in this study, since we recruited only female subjects. The effects 
of comorbid diagnosis [38], suicidal behaviour [23,24,25], alcoholism [39], or the effects of 
different medications  [24, 36]  were ruled out by the study exclusion criteria. To avoid the 
influence of the daylight exposure on platelet 5-HT values [40] patients and controls were 
sampled at the same time. Different phases of the menstrual status might influence platelet 5-
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HT concentrations, platelet MAO-B activity and serum T4 and TSH values. However, no 
significant differences in whole blood 5-HT [41], serum T3 and T4 [42] levels were detected 
in healthy women during follicular, ovulatory or luteal phases of the menstrual cycle. 
Although a positive correlation between platelet 5-HT concentration and plasma estrogen 
levels was found  [43], we have shown similar platelet 5-HT concentration between 
premenopausal and postmenopausal healthy, depressed and schizophrenic women [44]. Our 
results showed that platelet 5-HT concentrations were reduced in hypothyroid patients, and 
these data might be in line with hypothyroidism-induced reduction of central 5-HT activity, 
since reduced responses to both cortisol and prolactin (index of central 5-HT responsivity) to 
d-fenfluramine (centrally acting 5-HT releasing agent) were found in hypothyroid patients 
[15].  
The decrease in platelet 5-HT concentration in the present study suggests a reduced 5-HT 
synthesis or increased metabolism. Preclinical data showed a decreased activity of the 
tryptophan hydroxylase, a rate limiting enzyme involved in the biosynthesis of 5-HT, in 
animals with experimentally induced hypothyroidism [7].  
         The reduced platelet 5-HT concentration from our study could be related to the 
increased metabolism of 5-HT, due to the altered activity of MAO in patients with severe 
hypothyroidism. However, female hypothyroid patients and control subjects had similar 
platelet MAO-B activity (present study), and MAO-B activity was not affected by thyroid 
hormones in the rat brain [45], indicating that thyroid hormone status did not alter 
significantly platelet MAO-B activity. Platelet MAO-B activity might be affected by various 
factors such as gender, age, ethnicity, smoking, some neurodegenerative diseases, medication 
[46], and to control for these variables, the present study included only medication-free 
female Caucasian patients with no neurodegenerative diseases matched for age with control 
subjects, and all participants were nonsmokers. Even though 5-HT is not a main substrate for 
MAO-B [46], since MAO-A preferentially metabolizes 5-HT, it has been shown that MAO-B 
could be involved in the direct regulation of 5-HT synthesis in the rat brain [47] and platelet 
MAO-B activity has been proposed to be an indicator of the central 5-HT system [46]. 
Preclinical studies suggest that brain and thyroid and thyroid MAO-A activity was slightly 
increased in hypothyroid rats. [45]. Since we did not determine MAO-A activity in our 
hypothyroid patients and control subjects, and there are no literature data regarding peripheral 
MAO-A activity in hypothyroid patients, we could only speculate that decreased 5-HT in 
patients with hypothyroidism might have been induced with an increased MAO-A activity.  
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         We have found a positive correlation between platelet 5-HT concentration and platelet 
MAO-B activity and between T4 levels and platelet MAO-B activity in control participants, 
whose thyroid hormonal status and platelet biochemical markers were within the normal 
range. The lack of correlation between platelet 5-HT, MAO-B activity and T4 levels in 
patients with severe hypothyroid state suggests an altered and more complex relationship 
between HPT axis and 5-HT, which might be due to the reduced T4 and platelet 5-HT 
concentrations.  
          If platelet 5-HT concentration might be used as a limited peripheral indicator of the 
central 5-HT function [22,24,26] the results from the present study indicate that hypothyroid 
patients have lower platelet 5-HT concentration and possibly reduced central 5-HT function. 
Hypothyroid patients frequently experience depressive symptoms [48], and depressive 
patients [23,24], similarly to our hypothyroid patients, have decreased platelet 5-HT 
concentration. In addition, the addition of T3 or T4 to antidepressant therapy improved the 
clinical state in treatment resistant depressed patients [13]. Our results are in line with the 
significantly lower platelet 5-HT concentration in medication-free depressed patients 
compared to healthy controls [23,24]. The limitation of the present study was that patients 
were not evaluated with the scales or questionnaires for the presence of depressive symptoms. 
Our biochemical findings raise a question about a duration of withdrawal of T4 replacement 
therapy. Namely, withdrawal of 4 weeks duration might have severe consequences on medical 
status of the patients, as it has been shown that total thyroidectomy is associated with higher 
psychiatric morbidity than partial thyroidectomy [49]. In addition, preclinical studies showed 
that as early as 7 and 20 days following thyroidectomy neuronal proliferative capacity [50] 
and synaptic 5-HT levels [51] are reduced. To prevent a possible neuronal damage caused by 
4 weeks of severe hypothyreosis [50], we and others [48] propose a reduction of the duration 
of T4 withdrawal from 4 weeks to 3 weeks, and/or reduction of T4 replacement dosage to half 
the usual amount instead of the complete withdrawal in patients preparing for scintiscanning.   
          In conclusion, hypothyroid patients had decreased platelet 5-HT concentrations, similar 
platelet MAO-B activity, higher TSH and lower T4 levels than euthyroid healthy subjects. 
There were no significant correlations between platelet biochemical markers and thyroid 
hormones in hypothyroid patinets, suggesting that hypothyroid patients have an altered 
interaction between 5-HT system and HPT axis activity, presumably mediated by the reduced 
5-HT-induced regulation of the HPT axis activity. Our results also indicate that the use of 
routine peripheral 5-HT measurements (a few times during the hormone withdrawal 
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procedure) might be a diagnostic tool for evaluation of depressive symptoms in hypothyroid 
patients. 
 
 
  Acknowledgements 
         This study was supported by the Croatian Ministry of Science, Education and Sport grants  
 098-0982522-2457 and 098-0982522-2455. The authors would like to thank the nursing staff 
of the Department of Nuclear Medicine and Radiation Protection, University Hospital Zagreb, 
Clinical Hospital Center Zagreb, for the help with collecting blood samples. 
 
References  
 
1. Ahmed OM, El-Gareib AW, El-bakry AM, El-Tawab SMA, Ahmed RG: Thyroid 
hormones states and brain development interactions. Int J Devl Neuroscience 2008; 26:147-
209. 
 
2. Bauer M, Heinz A, Whybrow PC: Thyroid hormones, serotonin and mood: of synergy and 
significance in the adult brain. Mol Psychiat 2002; 7 :140-156. 
 
3. Sandrini M, Vitale G, Vergoni AV, Ottani A, Bertolini A: Effect of acute and chronic 
treatment with triiodothyronine on serotonin levels and serotonergic receptor subtypes in the 
rat brain. Life Sci 1996; 58: 1551-1559. 
 
4. Strawn  JR, Ekhator NN, D’Souza BB, Geraciotti TD, Geraciotti JR: Pituitary-thyroid state 
correlates with central dopaminergic and serotonergic activity in healthy humans. 
Neuropsychobiol 2004; 49: 84-87.  
 
5. Newman M, Agid O, Gur E, Lerer B: Pharmacological  mechanisms of T3 augmentation of 
antidepressant action. International J Neuropsychopharmacol 2003; 3: 187-191. 
 
6. Viquerie N, Langin D: Effects of thyroid hormone and gene expression. Curr Opin Clin 
Nutr and Metab Care 2003; 6: 377-381. 
 
 10 
7. Singhal RL, Rastogi RB, Hrdina PD: Brain biogenic amines and altered thyroid function. 
Life Sci 1975;  17 : 1617-1626. 
 
8. Ito JM, Valcana T, Timiras PS: Effect of hypo- and hyperthyroidism on regional monamine 
metabolism in the adult rat brain. Neuroendocrinology 1977; 24: 55-64. 
 
9. Savard P, Merand Y, DiPaolo T, Dupont A: Effect of neonatal hypothyroidism on the 
serotonin system of the rat brain. Brain Res 1984; 292: 99-108. 
 
10. Henley  WN, Chen X, Klettner C, Bellush LL, Notestine MA: Hypothyroidism increases 
serotonin turnover and sympathetic activity in the adult rat. Can J Physiol Pharmacol 1991; 
69:205-201. 
 
11. Vanderpump MP, Tunbridge WM: Epidemiology and prevention of clinical and 
subclinical hypothyroidism. Thyroid  2002; 12:839-847. 
                                                                                                                                                                                                           
12. Forman-Hoffman V, Philibert RA: Lower TSH and higher T4 levels are associated with 
current depressive syndrome in young adults. Acta Psychiatr Scand 2006; 114: 132-139. 
 
13. Łojko D, Rybakowski JK. L-thyroxine augmentation of serotonergic antidepressants in 
female patients with refractory depression. J Affect Disord DOI:10.1016/j.jad.2007.01.016 
 
14. Sjöberg  S, Eriksson M, Nordin C: L-thyroxine treatment and neurotransmitter levels in 
the cerebrospinal fluid of hypothyroid patients: a pilot study. Eur J Endocrinol 1998; 139: 
493-497. 
 
15. Cleare AJ, McGregor A, Keane VO: Neuroendocrine evidence for an association between 
hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol 1995 ; 43: 
713-719. 
 
16. Kulikov A, Moreau X, Jeanningros R: Effects of experimental hypothyroidism on 5-
HT1A, 5-HT2A receptors, 5-HT uptake sites and tryptophan hydroxylase activity in mature 
rat brain. Neuroendocrinology 1999; 69 : 453-459.   
 
 11 
17. Nemeroff CB. Recent advances in the neurobiology of depression. Psychopharmacol Bull 
2002; 36(2):6-23. 
 
18. Moorley JE. Neuroendocrine control of thyrotropin secretion. Endocrine Rev 1981; 2:396-
436. 
 
19. Howland RH. Thyroid dysfunction in refractory depression: implications for 
pathophysiology and treatment. J Clin Psychiatry 1993;54:47-54. 
 
20.  Nemeroff CB. Clinical significance of psychoneuroendocrinology in psychiatry: focus on 
the thyroid and adrenal. J Clin Psychiatry 1989; 50(5): 13-20. 
 
21. Prange AJ, Wilson IC, Lara PP, Alltop LB, Breese GR. Effects of thyrotropin-releasing 
hormone in depression. Lancet 1972; 2:999-1002. 
 
22. Bianchi M, Moser C, Lazzarini C, Vecchiato E, Crespi F: Forced swimming test and 
fluxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors 
cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT 
changes. Exp Brain Res 2002; 143: 191-197.  
 
23. Muck-Šeler D, Jakovljević M, Pivac N: Platelet 5-HT concentrations and suicidal 
behaviour in recurrent major depression. J Affect Disord 1996; 39: 73-80. 
 
24. Muck-Seler D, Pivac N, Sagud M, Mustapic M, Jakovljevic M: The effects of serotonin 
uptake inhibitors on platelet serotonin: From basic to clinical research; in Shirley AC (ed): 
Trends in Serotonin Uptake Inhibitors Research. NY: Nova Science Publishers, Inc., 2005, 
Chapter II, pp 29-53.  
 
25. Muck-Seler D, Pivac N, Jakovljević M:  Sex differences, season of birth and platelet 5-HT 
levels in schizophrenic patients. J Neuronal Transm 1999; 106:337-347. 
 
26. Pivac N, Muck-Seler D, Mustapic M, Sagud M, Darko Marcinko D, Deželjin M, 
Jakovljevic M  Peripheral biological markers and treatment response in schizophrenia; in  
 12 
French DP (ed): Schizophrenic Psychology: New Research. NY : Nova Science  Publishers, 
Inc. 2006; Chapter 15, pp. 319-370. 
 
27. Blardi P,  Palazzuoli A, de Lalla A, Auteri A. Variations of peripheral markers of 
serotoninergic system in selected vascular patients. Nutr, Metab Cardiovasc Dise (2006) 16: 
210-214. 
 
28. Fogel WA, Lewinski A and Jochem J. Histamine in food: is there anything to worry about ? 
Biochem Soc Trans 2007; 35:349-352. 
 
29. Fetkovska N. Platelet activation by low-density lipoprotein and serotonin: the effects of 
calcium antagonists. J Cardiovasc Pharmacol 1992; 19(3):S25-8. 
 
30. Oreland L, Hallman J, Damberg M. Platelet MAO and personality-function and dysfunction. 
Curr Med Chem 2004; 11(15):2007-16. 
 
31. Fagervall I, Ross SB. A and B forms of monoamine oxidase within the monoaminergic 
neurons of the rat brain. J Neurochem 1986; 47(2): 569-76. 
 
32. Licata G, Davi G, Scaglione R, Dichiara MA, Catalano I, Strano A. Platelet function in hypo- 
and hyperthyroidism. Boll Soc Ital Biol Sper 1989; 65(9):847-52. 
 
33. Ford HC, Carter JM. Moderate, chronic hypothyroidism does not lead to more small-sized 
platelets in the circulation. Thromb Haemost 1988; 60(3): 524. 
 
34. Coban E, Yazicioglu G, Ozdogan M. Platelet activation in subjects with subclinical 
hypothyroidism. Med Sci Monit 2007; 13(4): 211-4. 
 
35. Guimaraes V, DeGroot LJ. Moderate hypothyroidism in preparation for whole body 131I 
scintiscans and thyroglobulin testing. Thyroid 1996; 6(2):69-73. 
 
36. Mück-Šeler D,  Pivac N, Sagud M,  Jakovljević M, Mihaljevic-Peleš A. The effects of 
paroxetine and tianeptine on peripheral biochemical markers in major depression.  Prog  
Neuropsychopharmacol Biol Psychiatry 2002;  26: 1235-1243. 
 13 
 
37. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin 
phenol reagent. J Biol Chem 1951; 193(1):265-75. 
 
38. Mueller-Oerlinghausen B, Roggenbach J, Franke L: Serotonergic platelet markers of 
suicidal behaviour – do they really exist? J Affect Disord 2004; 79: 13-24. 
 
39. Pivac N, Kozarić-Kovačić D, Mustapić M, Deželjin M, Nenadić-Šviglin K, Muck-Šeler D 
(2007) New research on alcohol abuse and alcoholism (Peripheral biological markers in 
alcoholism) Chapter I.  In: Drug and Alcohol abuse Research Focus.  Ed: Walcott, Terry A. 
New York, Nova Publishers, pp 1-62. 
 
40. Ljubicic D, Stipcevic T, Pivac N, Jakovljevic M, Muck-Seler D: The influence of daylight 
exposure on platelet 5-HT levels in patients with major depression and schizophrenia. J 
Photochem Photobiol B: Biology 2007; 89:63-69. 
 
41. Rasgon N, McGuire M, Tanavoli S, Fairbanks L, Rapkin A: Neuroendocrine response to 
an intravenous L-tryptophan challenge in women with premenstrual syndrome. Fertil and 
Steril 2000; 73: 144– 149. 
 
42. Leibenluft  E, Fiero PL, Rubinow DR:  Effects of menstrual cycle on dependent vriables 
in mood disorder research. Arch Gen Psychiatry  1994; 51: 761– 781. 
 
43. Guicheney P, Leger D, Barrat J, Trevoux R, De Lignieres B, Roques P, Garnier JP, 
Boyers, P, Grenier J, Dreux C, Meyer P: Platelet serotonin content and plasma tryptophan in 
peri- and post-menopausal women: variations with plasma estrogen levels and depressive 
symptoms. Eur J Clin Investigation 1988;18: 297– 304. 
 
44. Muck-Seler D, Pivac N, Mustapic M, Crncevic Z, Jakovljevic M, Sagud M: Platelet 
serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. 
Psychiatry Res 2004; 127:217-226. 
 
45. Vaccari A, Biassoni R, Timiras P: Selective effects of neonatal hypothyroidism on 
monoamine oxidase activities in the rat brain. J of Neurochem 1983; 40(4):1019-1025. 
 14 
 
46. Oreland L: Platelet monoamine oxidase, personality and alcoholism: The rise, fall and 
resurrection. Neurotoxicology 2004; 25: 79-89.  
 
47. Nishi K, Mück-Šeler D, Hasegawa S, Watanabe A, Diksic M: Acute effects of 
moclobemide and deprenyl on 5-HT synthesis rates in the rat brain: An autoradiographic 
study. Brain Res Bull 2006; 70:368-377. 
 
48. Denicoff KD, Joffe RT, Lakshmanan MC, Robbins J, Rubinow DR: Neuropsychiatric 
manifestations of altered thyroid state. Am J Psychiatry 1990; 147(1):94-99. 
 
49.  Berrios GE, Leysen A, Samuel C, Dowson J. Psychiatric morbidity following total and 
partial thyroidectomy. Acta Psychiatr Scand 1985; 72(4):369-73. 
 
50.  Montero-Pedrazuela A, Venero C, Lavado-Autric R, Fernandez-Lamo I, Garcia-Verdugo 
JM, Bernal J. Modulation of adult hippocampal neurogenesis by thyroid hormones: 
implications in depressive-like behavior. Mol Psychiat 2006; 11: 361-371. 
 
51. Tejani-Butt SM, Yang J, Kaviani A. Time course of altered thyroid states on 5-HT1A 
receptors and 5-HT uptake sites in rat brain: an autoradiographic analysis. 
Neuroendocrinology 1993; 57(6):1011-8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
FIGURE LEGENDS 
 
Figure 1. Platelet serotonin (5-HT) concentrations in hypothyroid patients an euthyroid 
control subjects. Each column represents mean ± SD. Number of subjects is given in 
parenthesis. *P<0.001 vs. healthy controls (Mann-Whitney t-test). 
 
 
Table 1. Thyroxine (T4) and thyroid stimulating hormone (TSH) levels in euthyroid healthy 
controls and hypothyroid patients. Results are expressed as mean ± SD. Number of subjects is 
given in parenthesis. 
 
 
*P<0.001 vs. euthyroid controls (Mann Whitney t-test) 
 T4 
(nmol / L) 
TSH 
(mIJ / L) 
Platelet MAO 
(nmol4OHQ/mg p/h) 
Euthyroid controls (30) 120.4 ± 20.6*  1.52  ±  0.89* 18.98 ± 12.14 
Hypothyroid patients (25) 22.1 ± 8.3 92.07 ±  30.28 19.93 ± 5.72 
